About Crossject

Company Description

Crossject is revolutionizing the administration of well-established, clinically-proven treatments and bringing unprecedented advantages to patients with its innovative, needle-free auto-injector ZENEO®.
ZENEO® is no less than 12 years of R&D and more than 400 obtained patents.

Currently, 8 treatments are in advanced stages of development, which 7 for emergency situations.
With its unique know-how, Crossject aims to become a world leader in the self-administration of emergency needle free injectables.

Year founded

2001

Served area

Worldwide

Headcount

100

Headquarters

Parc Mazen-Sully 6 Rue Pauline Kergomard, 21000 Dijon – France

Shareholder information

Shares outstanding

26,589,947

IPO

Feb. 20, 2014

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.